^
    1d
    Gene expression-based machine learning model for diagnosis, prognosis, and treatment response prediction in hepatocellular carcinoma: a retrospective study. (PubMed, J Yeungnam Med Sci)
    Our gene expression-based machine learning model provides a robust tool for HCC diagnosis, prognosis, and treatment response prediction, with potential as a supportive system for personalized clinical decision-making.
    Retrospective data • Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • CDK1 (Cyclin-dependent kinase 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • RACGAP1 (Rac GTPase activating protein 1)
    |
    sorafenib
    1d
    Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives. (PubMed, Bioorg Chem)
    Several compounds exhibited strong VEGFR-2 inhibition, with activities comparable to or exceeding that of sorafenib, but lower than sunitinib. Cytotoxicity assays against MCF-7 breast cancer cells revealed five derivatives (4, 7, 9, 10, and 12) more active than doxorubicin along with five additional compounds showing comparable potency. In contrast, the compounds displayed moderate cytotoxic activity against the MDA-MB-231 cell line and none showed significant toxicity toward MCF-10A  normal breast epithelial cells. Mechanistic studies of compound 10 demonstrated G0/G1 phase arrest, apoptosis induction, and increased ROS generation, suggesting its potential as a selective and effective lead for breast cancer therapy.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    sorafenib • sunitinib • doxorubicin hydrochloride
    2d
    Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib. (PubMed, Haematologica)
    We analyzed 523 adults with FLT3-ITD AML in first complete remission who underwent allo-HCT between 2011 and 2023 in 13 German transplant centers participating in the national DRST registry; 22% received FLT3i maintenance (sorafenib 49%, midostaurin 37%, gilteritinib 5%, unknown 9%). Sorafenib maintenance (n=50) demonstrated superior efficacy with 5-year OS of 85% versus 62% (HR 2.979, p=0.0045) and RFS of 84% versus 55% (HR 2.771, p=0.0043) compared to no maintenance. These real-world findings, while limited by the retrospective design and potential selection bias, align with randomized trial data and support the use of FLT3i maintenance as part of post-transplant care for FLT3-ITD AML.
    Journal • Real-world evidence
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    sorafenib • Xospata (gilteritinib) • midostaurin
    3d
    Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma (clinicaltrials.gov)
    P2, N=45, Recruiting, Hanmi Pharmaceutical Company Limited
    New P2 trial
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Cotellic (cobimetinib) • belvarafenib (RG6185)
    3d
    RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression. (PubMed, Front Oncol)
    Our findings demonstrate that RPL28 contributes to sorafenib resistance in HCC by upregulating CDC6, contributing to tumor proliferation and drug resistance. The newly identified RPL28-CDC6 axis represents a novel mechanism of resistance and a potential therapeutic target to overcome treatment limitations in HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CDC6 (Cell Division Cycle 6) • TRAF6 (TNF Receptor Associated Factor 6)
    |
    PD-L1 expression
    |
    sorafenib
    4d
    JPMS-DTC: Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (clinicaltrials.gov)
    P=N/A, N=453, Active, not recruiting, Bayer | Trial completion date: Nov 2025 --> Sep 2026
    Trial completion date
    |
    sorafenib
    4d
    DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) (clinicaltrials.gov)
    P3, N=400, Recruiting, Day One Biopharmaceuticals, Inc. | Trial completion date: Mar 2030 --> Jun 2031 | Trial primary completion date: Feb 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    carboplatin • Ojemda (tovorafenib)
    5d
    A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Ipsen
    New P1 trial
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF mutation • BRAF V600 • BRAF fusion
    |
    Ojemda (tovorafenib)
    5d
    DCC-3084-01-001: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway (clinicaltrials.gov)
    P1, N=29, Terminated, Deciphera Pharmaceuticals, LLC | Phase classification: P1/2 --> P1 | N=140 --> 29 | Trial completion date: Aug 2027 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Feb 2026; Trial terminated due to a business decision, not based on any safety concerns.
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • NF1 (Neurofibromin 1) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
    |
    BRAF mutation
    |
    DCC-3084
    5d
    Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. (PubMed, J Immunother Precis Oncol)
    The lack of clinical efficacy may be due to inadequate inhibition of RAS-to-ERK signaling as toxicities necessitated dose reduction. NCT05068752.
    P2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Zelboraf (vemurafenib) • sorafenib
    7d
    Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms. (PubMed, Biochim Biophys Acta Rev Cancer)
    We synthesize recent advances linking these molecular axes to ferroptosis pathways, discuss their crosstalk in sorafenib-resistant HCC, and underscore emerging therapeutic strategies that leverage pharmacological or radiotherapeutic targeting of these mechanisms. A deeper understanding of this regulatory network may inform rational combination therapies aimed at resensitizing advanced HCC to sorafenib.
    Review • Journal
    |
    GPX4 (Glutathione Peroxidase 4) • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • ABCC5 (ATP Binding Cassette Subfamily C Member 5) • ATF4 (Activating Transcription Factor 4) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2)
    |
    sorafenib
    7d
    SEACRAFT-1: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Erasca, Inc. | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    RAS mutation
    |
    Mekinist (trametinib) • naporafenib (ERAS-254)